Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta‑analysis with comparison of different types of hepatitis

Zhang,Wei; Song,Tian‑Qiang; Zhang,Ti; Wu,Qiang; Kong,Da‑Lu; Li,Qiang; Sun,Hui‑Chuan

doi:10.3892/mco.2014.386

Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta‑analysis with comparison of different types of hepatitis

Authors:
- Wei Zhang
- Tian‑Qiang Song
- Ti Zhang
- Qiang Wu
- Da‑Lu Kong
- Qiang Li
- Hui‑Chuan Sun
View Affiliations

Affiliations: Key Laboratory of Cancer Prevention and Therapy, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Key Laboratory for Carcinogenesis and Cancer Invasion, Liver Cancer Institute and Zhongshan Hospital, Fudan University, The Chinese Ministry of Education, Shanghai 200032, P.R. China
Published online on: August 12, 2014 https://doi.org/10.3892/mco.2014.386
Pages: 1125-1134

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adjuvant interferon (IFN) therapy following curative treatment for hepatocellular carcinoma (HCC) has been extensively investigated; however, the clinical benefits with different hepatitis backgrounds remain unclear. Medline, Embase, PubMed and the Cochrane Library databases were searched to identify randomized trials and cohort studies that enrolled HCC patients who received curative surgery or ablation therapy followed by IFN and control subjects; the studies were required to include data on early or late recurrence and mortality rates of HCC. Hepatitis B virus (HBV) associated with HCC (HBV‑HCC) and hepatitis C virus (HCV) associated with HCC (HCV‑HCC) were separately analyzed and recurrence, mortality and clinicopathological factors were compared. A total of 14 studies (9 randomized trials and 5 cohort studies, including 1,385 patients in total) were eligible for meta‑analysis. IFN was found to decrease mortality and early recurrence rates, but exerted no effect on late recurrence rate. The effect of IFN differed between HBV‑HCC and HCV‑HCC cases. in HCV‑HCC, IFN significantly reduced mortality as well as recurrence rates. However, in HBV‑HCC patients, IFN reduced mortality rather than recurrence rates, although it also reduced the recurrence rate in certain subgroups. In conclusion, the effect of adjuvant IFN on postoperative recurrence differed between HBV‑HCC and HCV‑HCC cases; therefore, different strategies with adjuvant IFN should be used to treat HCC with different hepatitis backgrounds.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Zhong JH, Li H, Li LQ, et al: Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 38:286–295. 2012. View Article : Google Scholar : PubMed/NCBI
3	Poon RT, Fan ST, Ng IO, et al: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 89:500–507. 2000. View Article : Google Scholar : PubMed/NCBI
4	Mazzaferro V, Romito R, Schiavo M, et al: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 44:1543–1554. 2006. View Article : Google Scholar : PubMed/NCBI
5	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
6	Chen L, Zhang Q, Chang W, et al: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 48:1977–1987. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wu JC, Huang YH, Chau GY, et al: Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 51:890–897. 2009. View Article : Google Scholar : PubMed/NCBI
8	Imamura H, Matsuyama Y, Tanaka E, et al: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 38:200–207. 2003. View Article : Google Scholar : PubMed/NCBI
9	Hoshida Y: Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J Hepatol. 51:842–844. 2009. View Article : Google Scholar : PubMed/NCBI
10	Clavien PA: Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 245:843–845. 2007. View Article : Google Scholar : PubMed/NCBI
11	Oikawa T, Ojima H, Yamasaki S, et al: Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. J Hepatol. 42:225–229. 2005. View Article : Google Scholar : PubMed/NCBI
12	Wang L, Wu WZ, Sun HC, et al: Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg. 7:587–594. 2003. View Article : Google Scholar : PubMed/NCBI
13	Lo CM, Liu CL, Chan SC, et al: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 245:831–842. 2007. View Article : Google Scholar : PubMed/NCBI
14	Lin SM, Yu ML, Lee CM, et al: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 46:45–52. 2007. View Article : Google Scholar : PubMed/NCBI
15	Miyake Y, Takaki A, Iwasaki Y and Yamamoto K: Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 17:287–292. 2010. View Article : Google Scholar
16	Shen YC, Hsu C, Chen LT, et al: Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol. 52:889–894. 2010. View Article : Google Scholar : PubMed/NCBI
17	Singal AK, Salameh H, Kuo YF and Fontana RJ: Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 38:98–106. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sun HC, Tang ZY, Wang L, et al: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 132:458–465. 2006. View Article : Google Scholar
19	Chen LT, Chen MF, Li LA, et al: Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon alpha-2b in hepatocellular carcinoma after curative resection. Ann Surg. 255:8–17. 2012. View Article : Google Scholar
20	Jeong S, Aikata H, Katamura Y, et al: Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol. 13:5188–5195. 2007. View Article : Google Scholar
21	Kudo M, Sakaguchi Y, Chung H, et al: Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 72(Suppl 1): 132–138. 2007. View Article : Google Scholar
22	Kubo S, Nishiguchi S, Hirohashi K, et al: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 89:418–422. 2002. View Article : Google Scholar
23	Breitenstein S, Dimitroulis D, Petrowsky H, et al: Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 96:975–981. 2009. View Article : Google Scholar : PubMed/NCBI
24	Zhang CH, Xu GL, Jia WD and Ge YS: Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer. 124:2982–2988. 2009. View Article : Google Scholar
25	Nishiguchi S, Kuroki T, Nakatani S, et al: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1051–1055. 1995. View Article : Google Scholar : PubMed/NCBI
26	Sung JJ, Tsoi KK, Wong VW, et al: Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 28:1067–1077. 2008. View Article : Google Scholar : PubMed/NCBI
27	Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 32:228–232. 2000. View Article : Google Scholar
28	Budhu A, Forgues M, Ye QH, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 10:99–111. 2006. View Article : Google Scholar : PubMed/NCBI
29	Huang JF, Yu ML, Huang CF, et al: The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. J Hepatol. 54:219–226. 2011. View Article : Google Scholar
30	Hung IF, Poon RT, Lai CL, et al: Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 103:1663–1673. 2008. View Article : Google Scholar : PubMed/NCBI
31	Yin J, Li N, Han Y, et al: Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 31:3647–3655. 2013. View Article : Google Scholar
32	Huang G, Yang Y, Shen F, et al: Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol. 20:1482–1490. 2013. View Article : Google Scholar : PubMed/NCBI
33	Yang JQ, Pan GD, Chu GP, et al: Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol. 14:5564–5569. 2008. View Article : Google Scholar
34	Yamazaki K, Suzuki K, Ohkoshi S, et al: Temporal treatment with interferon-beta prevents hepatocellular carcinoma in hepatitis B virus X gene transgenic mice. J Hepatol. 48:255–265. 2008. View Article : Google Scholar : PubMed/NCBI
35	Qian YB, Zhang JB, Wu WZ, et al: P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer. 107:1562–1569. 2006. View Article : Google Scholar
36	Ji J, Shi J, Budhu A, et al: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 361:1437–1447. 2009. View Article : Google Scholar : PubMed/NCBI
37	Suou T, Mitsuda A, Koda M, et al: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res. 20:301–311. 2001. View Article : Google Scholar : PubMed/NCBI
38	Miyaguchi S, Watanabe T, Takahashi H, et al: Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology. 49:724–729. 2002.PubMed/NCBI
39	Shiratori Y, Shiina S, Teratani T, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 138:299–306. 2003. View Article : Google Scholar : PubMed/NCBI
40	Jeong SC, Aikata H, Katamura Y, et al: Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol. 13:5343–5350. 2007. View Article : Google Scholar
41	Hagihara H, Nouso K, Kobayashi Y, et al: Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol. 16:210–220. 2011. View Article : Google Scholar